No matter how cynical the overall market is, Ovid Therapeutics Inc (OVID) performance over the last week is recorded -1.60%

Ovid Therapeutics Inc (NASDAQ: OVID) kicked off on Friday, down -4.65% from the previous trading day, before settling in for the closing price of $1.29. Over the past 52 weeks, OVID has traded in a range of $0.24-$1.47.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

During the last 5-year period, the sales growth of Healthcare Sector giant was 24.72%. While this was happening, its average annual earnings per share was recorded -35.91%. With a float of $59.50 million, this company’s outstanding shares have now reached $71.11 million.

Ovid Therapeutics Inc (OVID) Breakdown of a Key Holders of the stock

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ovid Therapeutics Inc is 16.33%, while institutional ownership is 34.63%. The most recent insider transaction that took place on Feb 26 ’25, was worth 2,956. In this transaction President and COO of this company sold 5,279 shares at a rate of $0.56, taking the stock ownership to the 73,406 shares. Before that another transaction happened on Feb 26 ’25, when Company’s CBFO sold 3,902 for $0.56, making the entire transaction worth $2,185. This insider now owns 67,973 shares in total.

Ovid Therapeutics Inc (OVID) Recent Fiscal highlights

In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.2 earnings per share (EPS), higher than consensus estimate (set at -0.23) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.

Ovid Therapeutics Inc (NASDAQ: OVID) Trading Performance Indicators

Take a look at Ovid Therapeutics Inc’s (OVID) current performance indicators. Last quarter, stock had a quick ratio of 4.72. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.15.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.54, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.57 in one year’s time.

Technical Analysis of Ovid Therapeutics Inc (OVID)

Looking closely at Ovid Therapeutics Inc (NASDAQ: OVID), its last 5-days average volume was 1.36 million, which is a jump from its year-to-date volume of 1.02 million. As of the previous 9 days, the stock’s Stochastic %D was 82.43%.

During the past 100 days, Ovid Therapeutics Inc’s (OVID) raw stochastic average was set at 89.80%, which indicates a significant increase from 78.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1140 in the past 14 days, which was higher than the 0.0526 volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $0.6881, while its 200-day Moving Average is $0.6080. However, in the short run, Ovid Therapeutics Inc’s stock first resistance to watch stands at $1.3167. Second resistance stands at $1.4033. The third major resistance level sits at $1.4767. If the price goes on to break the first support level at $1.1567, it is likely to go to the next support level at $1.0833. Now, if the price goes above the second support level, the third support stands at $0.9967.

Ovid Therapeutics Inc (NASDAQ: OVID) Key Stats

The company with the Market Capitalisation of 87.46 million has total of 71,110K Shares Outstanding. Its annual sales at the moment are 570 K in contrast with the sum of -26,430 K annual income. Company’s last quarter sales were recorded 6,270 K and last quarter income was -4,680 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.